List of Halaven drug patents
Halaven is owned by Eisai Inc.
Halaven contains Eribulin Mesylate.
Halaven has a total of 4 drug patents out of which 0 drug patents have expired.
Halaven was authorised for market use on 15 November, 2010.
Halaven is available in solution;intravenous dosage forms.
The generics of Halaven are possible to be released after 08 July, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6214865 | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jul, 2023
(5 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6214865
(Pediatric) | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jan, 2024
(11 months from now) | |
| USRE46965 | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jan, 2027
(3 years from now) | |
|
USRE46965
(Pediatric) | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jul, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jan 28, 2023 |
| M | Sep 13, 2025 |
| Pediatric Exclusivity (PED) | Mar 13, 2026 |
Drugs and Companies using ERIBULIN MESYLATE ingredient
Market Authorisation Date: 15 November, 2010
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic